期刊文献+

进展期胃癌合并恶性腹水术前双路化疗的应用价值 被引量:2

Evaluation of two route-chemotherapy for advanced gastric cancer ascites
下载PDF
导出
摘要 目的探讨进展期胃癌合并恶性腹水术前双路化疗的效果。方法对42例进展期胃癌合并恶性腹水患者采用术前双路化疗,5-FU、MMC方案同时应用绿慕安腹腔注射,绿慕安5ml/50kg、5-FU400mg/m2、MMC6mg/m2,同时静脉予LV5FU2OXA化疗。结果显效(CR)24例,部分有效(PR)10例,无变化(NC)8例。获得CR+PR的34例,行姑息手术治疗22例,切除率为52.4%(22/42)。结论术前应用双路化疗,为高度进展期胃癌的综合治疗开辟了一条新途径。 Objective To evaluate the effects of two route-chemotherapy for the patients with advanced gastric cancer ascites. Methods 42 cases of preoperative gastric cancer ascites were treated with intra-venous injection of 5-FU?MMC plus PA-MSHA. Subsequently, the patients were treated with intra-peritoneal injection of LV5FU2OXA. Results There was CR,PR,NC occurred in 24,10 and 8 cases respectively.22 of 34 CR+PR cases were operated. Conclusions Two route-chemotherapy inaugurates a new route of treatment for the synthesis therapy of preoperative gastric cancer ascites.
作者 杨巍
机构地区 辽宁省肿瘤医院
出处 《中国医药导报》 CAS 2006年第30期45-46,共2页 China Medical Herald
关键词 胃肿瘤 双路化疗 氟尿嘧啶 奥沙利铂 绿慕安 Stomach neoplasms two route-chemotherapy Fluorouracil L-OHP PA-MSHA
  • 相关文献

参考文献3

二级参考文献6

共引文献41

同被引文献6

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部